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SHIELDING PATENT ATTACKS: A PEEK INTO THE DEFENCES
AND

ExCEPTIONS TO A PATENT INFRINGEMENT SUIT
-Gunjan Chawla

Abstract:
The objective of granting parmi rights is to conftr monopoly rights, the rights to
t!Xciusive use and o:plaitation of one's invmtion to the (Xclusion of aLI the others.
Howroer, this esuntialiy "qui"s that the rights claimed may only be realiud ona the
claimed invmtion satisfies the thru sup test a/Novelty. lnvmtive step and Industrial
application. Any similarity or identity in the claims as made by the applicant may
be chaiknged before the paunt offia in an inJringmzmt suit against such infringer.
Aft'" the plaintiffrstabli,h" a prima facit cast in his favour, tht burdm ofproving
non-infringemmt shifts upon the defendant. Moreover, in India, there is no
presumption against the validity a/the grant ofpatent by me" registration. Hena,

tht validity ofa rtgistmd pattnt may be challenged by tht defendant when charges
ofinfring<rntnt havt bun levelled against him, and thus, he may absolve himsdfof
the liability. Hmu, th~ two major categories oftkfinces shall either involve a proD/of
non-infringnnmt - which shall require the ckftndant to prove that his patent claims
don't foil within the suspicion ofthe claims mack by the patenter in his application,
or invalidity ofthe pattnt - whtrtin tht tkfendant ,hall have to tkfend himselfby
raising tUJubts and qutstioning tht grant of the patent. Although tht rights of the
patrotu and their enforcement do find a place in almost all the kgislations across
tht world, not much tmphasis is laid on the tkfences that may ,hitld tht tkfendant
in successfully combating an allegation ofinfringemrot kvelled against him. Hence,
the present paper is an endeavour to identifY and meticulously discuss the various

drfinus that may bt availed by the tkfendant while he i, caught up in a legal battle
against the plaintiff, a briifcritical analysis ofthe same and the reforms that may
be made in order to ensure an efficrive and sucasiful application by the ckftndant.

Key Words: CIas, defences, Individualised tkfences, Gillette tkfence, Prosecution
History Estoppel. Reveru Doctrine of Equivalence. Bolar Exemption, Parall(!
Importation.
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A right is realised when it becomes enforceable under the law, and a right to
defend oneself is realised when the grounds for defence are allowed to prevail
under the law. A defence is a right that enables the defendant in an actionable
suit to absolve himself of the liability. Since it is a direct attempt to avoid
what would otherwise constitute a liability, the burden of proof shifts on the
defendant. It is this burden that is sought to be removed bv arming him with the
defences that shall shield the defendant against the accusations levelled against
h im . As in like the other laws, in Patents the defendant is confer red with an
equal right to defend himself against any or all the allegarions levelled aga inst
him by the plaintiff in regard to determining his liability for in fringement of
the patent.
A patent infringement suit comprises of two separate battles - one where
the plaintiff alleges infringement and claims damage for the same, and the
other where the defendant attempts to terminate the patent rights by proving
invalidity of patents or disproving infringement on his part. H ence, although
the initial burden of proving infringement li es upon the plaintiff, the real
burden of disptoving any infringement lies upon the defendant, and hence, as
such , a tacit application of one or more of the several defence; that are available
becomes crucial in deciding the fate of the allegation.

NUANCES OF A PATENT INFRINGEMENT SUIT
Unlike the Indian Copyright and Trademark Laws that specifically define
"infringement,'" the Patents Act provides it in the form of an enforcement right
under Section 48 , implied under the exclusive rights granted to the patentee
against a third party's unauthorised use. In Monsanto Canada Inc. v.Schmeiser, 2
it was defined to mean 'any act that interferes with the full enjoyment of the
monopoly granted to the patentee' or 'any activity that deprives the inventor,
in whole or in part, directly or indirectly, of full enjoyment of the monopoly

The Copyright Act, J 957, S. 2(m) r/w Section 51 ; The Trademark Atr, 1999, Section
29
2

(2004) I S.C.R. 902 at para. 34-35
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conferred by law.' Hence, it is the invention that defines the boundaries of the
monopoly rights that shall be conferred upon the patentee. l However, this
monopoly shall end if the limits of the claims as specified in the specification

•

by the patentee fall under the mischief of any of the grounds that culminate to
revoke his patent under section 64 or if the claims are absolutely beyond the
ambit of the patentable inventions. Hence, under these circumstances his claim
for infringement shall fail if the defendant succeeds in invalidating the patent
or proves non-infringement if the use by him falls under any of the express
limitations and exceptions that are excluded from amounting to infringement.
Patent Law imposes liability for an independent development. This implies
that even if a single claim made by the defendant falls within the subject
matter and scope of the claims made by patentee, the former may be held
liable. The fact of "intention to infringe" is irrelevant' Whereas "the fact of
accidental similarity" and "an honest concurrent use" is an admissible defence
under copyright and trademark laws, respectively; patent law merely offers the
alleged infringer to challenge the validity of the patent in order to defend the
allegation of infringement, thereby shifting the onus on the defendant. The
presumption as to the presupposition of the defendants' involvement in the
act of copying the patent is much higher than the presumption against the
validity of the patent. s
Patent infringement occurs when a product or process developed by the
defendant is claimed to infringe one or more patent claims made by the patentee.
Determination of patent infringement involves a two-step process - firstly a
product or process is analysed and compared with all relevant patents and their
specific claims in an invention similar to the product. Secondly, the product or
the process is scrutinized to see if the product or the process 'reads on' one or
3

Free World Trust v. Electro Santtlnc., [2000] 2 S.C.R. 1024 at para. 31

4

Christopher Cotropia, MarkA. Lemley, Copying in Patent Law,2008,(available at- https:!!
pdfs.semanticscholar.org/fb4d/f4 5b93bd87b24 2b 7b07 c2f9d2a3c I f4dad4b. pdO

5

This is nor applied and adhered to in all the jurisdictions, and in India this principle of
presumption against validity of the patentS is not followed. It is the patentee who has to

prove the fact ofinfringemenr by the defendam when he files a suit claiming infringement.
79
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more patents and substantially describes itself in the language of the claims of
the one or more patents. Hence. the patentee has to prove t at the very essence
of his invention. the claims and specifications that constitute the 'pith and
marrow' of his invention have been copied or taken by th,· alleged infringer.

D EFENCES TO PATENT INFRINGEMENT SUIT

It is axiomatic that a suit for patent infringement entails a .mier liabiliry upon
the alleged infringer, and the Court shall grant an injunction against the
defe ndant if the fact of infringement is proved. and may also be held liable to
pay damages or account of profits at the option of the plai tiff.6The defences
to patent infringement may broadly be categorised into three forms: Direct.
Indirect and Co ntributory Infringement. 7
Direct Infringement implies an infringement where the alleged infringer
commits the acts of selling, using, making or importing. of the patent for
commercial purposes without the consent of the patentee during the term
of the patent. In case of an Indirect Infringement. there i~ a third parry who
makes. uses or sells an embodiment of the invention without the consent of the
patentee as a consequence of deceit or accidental patent infr ingement. Further,
if such a product is knowingly supplied or sold then the same amounts to
Contributory Infringement. The fact of infringement shall have to be ptoved
by comparing the claims made by the defendant with that of the plaintiff. It is
here that the question of establishing infringement shall imolve an imperative
enquiry into the validiry of the patent.
In response to this. the defendant shall have to argue on two grounds: Invalidiry
of the patent and/or Non-infringement 8 The non-infn ngement defence

6

Indian Paunt Act, 1970, Section 108

7

PaUnt Infringement in India, IPRO services Lrd. India. , pA-5 (available at-http://www.
ipptoinc.coml admin /filesl uploadl dc8904b7508e513 55b25 fl>caOd386e8e. pdf) 2009

8

Roger Ford, Patent Invalidity vmus Infringnnmt, CORNELL LAw REVIEW, 20 13{available
a[-hnps:llwww.kcnrlaw.iic.edu / Docum ems/Academi c%20ProgramslI nrel leccual%20

Property/ PatCon3/Ford%20Paper.pdf)
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focuses on whether or not the defendants' product or process falls within the
monopoly rights that are conferred upon the inventor in lieu of his invention
and disclosure. It also includes cases where the defendant proves an authorised
use of the patented invention in the form of Government use, Bolar exemption
or parallel importation.' On the other hand, the defence of invalidity reexam ines the fulfilment of pre-requisite criteria for the grant of patents, i.e.,
whether the invention is novel , non-obvious and has been disclosed to the
world in compliance with the provisions of the patent law. 10
The defence of non-infringement merely argues on the line that the alleged
infringers' product doesn't fall within the suspicion of the limits claimed by
the patentee in the patent application and, hence, a case of infringement is far
from being made out. This can be determined by the application of the "all
elements rule" or "doctrine of equivalence" wherein the Courts shall begin
with construing the language in the claims made by the patentee and then a
comparison with the alleged infringing product to see ifit covers evety limitation
of the claims of the patent. In case it doesn't, then no infringement is ruled out.
The invalidity defence questions the validity of the patent and its grant, based
on the "state of art" available at the time when the patent was granted and
the threshold limit of the PHOSITA. Hence, it strikes at its authenticity on
the grounds of lack of novelty and inventive step - a sine qua non for getting
patents. This invalidity defence is fu rther based on three doctrines " :
Doctrine that satisfies the novelty and non-obviousness requirements, 12
Doctrine that fulfils the disclosure requirement"
Doctrine that covers those inventions which are patentable. J4
9

Indian PauntAct, 1970, S5. 107(b) 107A(a) and 107A(b)

10

Roger A. Ford, Patent Invalidity Versus Noninfringement. 99 Cornell Law Review,
p.7 (availab le at -h rrps: Ilwww.kenrlaw.iir. edu / Documents/Academic%20Programs/
i n rei iecruai % 20 PropertyIPa tCo n 31Ford % 2 0 Pa pe r. pdf)

1i

Andres Sawicki, Better Misrakrs in Patent Law, 39 FLA. ST. U. L. REV. 735, 742-44
(201 2)

12

See, Indian Patent Act, 1970, S. 64 (e)-(f).

13

Ibid, S. 10(4).

14

Ibid, S5. 3 and 4
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As far as the provisions under the Indian Patent Act are concerned, the invalidity
defence is implied under the following provisions:
t.

Section 64 which seeks to provide for revocation of a patent after it

has been granted. If the pre-requisite conditions prior to the filing
of the patent application and grant of such patent have not been
fulfilled as per the provisions under the Patents Act, '5 such grant
may be revoked.
It.

Section 25 which enumerates the grounds for pre-grant and post-

grant opposition of a patent after its publicatio . The oppositions
levelled by any person interested relate to the non-fulfilment of the
conditions prior to the filing of the patent application or after the
patent has been gtanted 16
ttl.

Section 107 which enumerates the grounds for efences to a patent

infringement suit under Section 64 in the form of counterclaims.
The most basic asymmetty between litigating invalidity an non-infringement
lies in the burden of proof; invalidity must be proved by clear and convincing
evidence, while infringement must be proved only by a preponderance of the
evidence. " Therefore, in an invalidity defence, the burden n the defendant is
substantially greater than that in the case of the latter. It is because of this reason
that generally the non-infringement defence is preferred over the invalidity
defence. Invalidity is a question about the asserted patem, so it depends on
information about that patent-its claims, specification, and prosecution
history-and information about the state of the world when the patent was
granted, and to that extent, the invalidity argument can be said to be based
on prior art. Non-infringement, on the other hand, is a question about the
accused product or process, so it depends on the features and workings of that
product or process. In fact, it is the claim construction in both these cases that
15

The Patents Act. 1970, Ss. 3, 6, 8, 9, 10,35,48

16

ibid

17

Microsoft Corp. v. i4i Ltd Partnership, 131 S. Ct. 2238 (2011) (invalidity); Centricut,
L.L.c. v. Esab Group, Inc., 390 F.3d 1361 ,1367 (Fed. Cir. 2004) (infringement).
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Shielding Patent Attacks: A Peek into The Defences and Exceptions to A Patent Infringement Suit

plays a very crucial role in determining the invalidity (on the basis of claim
construction of the prior art and the patent in question) or non-infringement
(determined on the basis of claims made by the alleged infringer and that of
the patent it is alleged to infringe).
(A) THE META-THEORY ON CLASSIFICATION OF DEFENCES

Apart from the above categories, according to the meta-theoty oflaw, all forms
of intellectual property can be said to be encompassed under three conceptual
catego ries of defences, namely: General, Individualised and Class defences. 18
This classification is based on the nature of the alleged infringement and the
nature of the infringer itself.
1.

General defences are those that challenge the validity of the patent itself
and the right of the patentee as the conditions for obtaining a patent
remain unfulfilled. It is such a defence that altogether negates the validity of
the patent in ftont of the entire world and annuls not only the defendant,
but also the entire world, of the duty to comply with it. Such defences
are enumerated under S. 107 r/w 64 of the Indian Patents Act, 1970, as
discussed above. Applicarion of these defences requires a comprehensive
and detailed enquity on part of the defendant into the claims made by the
patentee and prior art. Such defences may be likened to the concept of
rights in rem when applied inversely to the defences against the plaintiff. "

2.

Individualised defences are those where the defendant absolves himself
of the liability of any infringement on his part. Such defences are much
narrower because they are bent upon only defending the alleged infringer
in the particular suit itself and are generally classified as non-infringement
defences, where the defendant seeks to ptove no liability on his part, rather

18

Gideon, A. Stein, Intti"ctual Prop"'y D4enw, COLUMBIA LAw REVIEW, VOL 113, No.6
(OCTOBER 20 I 3)(available at- http://www.jsro r.org/stable/23561268)

19

Rights in rem are rights that are available against the whole world. This conception, when
applied inversely to the defenses available agai nst the plaintiff. shall have a similar effect
of being applicable by all the prospective defendants aga inst the plaintiff in the matter
relating [Q negating the validi ty of the patem.
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than attacking the rights of the patentee in relation to the patent. Thus,
the rights of the patentee remain intact. Hence, a successfully pleaded
individualised defence defeats the specific infringement claim in that
particular suit. These defences provide immunity to the defendant and
justifY the use of the impugned patent. The benefit of an individualized
defence accrues exclusively to the defendant who raises it, and his victory
does not change the legal status of other potential defendants . Examples
of such defences include: A claim that a later inventio doesn't fall under
the claims made by the defendant, Inequitable conduct on the part of
the plaintiff, Government use, Gillette defence, Reverse doctrine of
equivalents, etc. Co nceptually, therefore, individualized defences are
inverse of rights in personam,'· rights that avail only against a particular
individual.
3.

Class defences: Class defences form an in-berween category. They create
an immunity zone for a certain group of users to which the defendant
belongs, without nullifYing the plaintiff's right. Unlike general defences
that have the potential to negate the right asserted bv the plaintiff, and
individualized defences that do not impact the plaintiffs right against any
future defendants, class defences, when successful, block claims against a
specified class of defendants. Examples include Research and Experimental
use or Bolar Exemption and Parallel Importation. It t us tends to set up
a categorical bar against certain infringement claims, thereby protecting
a specified class or category of defendants . There are various Universities
and research institutes that make use of the inventio ns for the purpose
of further research or teaching. Similarly, the importation of patented
drugs by way of a legal sale for the purpose of distriburing it at lower and
cheaper prices to ensure its access to all shall ptovide immunity to such

20

Rights in pmonam are available only against the person who is r~ponsibl e for violating
the right of the plaintiff. There is only one defendant who is held liable for violation of
rights. In a similar way. an inverse application of this concept to the defences availab le at
rhe disposal of the defendant against rhe plaintiff can be said to be a defence wh ich only
he can use as a shield in a suit for infringement such that he can .lbsolve himself of me
liabilicy.
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generic companies or organisations against any claim of infringement.
Class defences are thus a conceptual mirror image of quasi-property rights,
as they protect the entire genre or category to which the defendant belongs.
Hence, the above discussion gives rise to the following propositions:

•

That general defences are a form ofinvalidiry defence that invalidate
a patent and an infringement claim as against a specific defendant
only.

•

That the individualised and class defences are forms of noninfringement defences. They negate the claims of infringement by
proving that the alleged infringement falls outside the scope of the
claims made by the patentee.

(B) TYPES OF INDIVIDUALISED DEFENCES

As has already been explained, these are such defences, the usage and application
of which depends upon the facts and circumstance of the case at hand and are
such that only protect the defendant against the claims of infringement, such
that he is able to prove non-infringement by pleading these defences, so as
to

absolve himself of the liabiliry alleged against him. Some of such defences

include the following:
a) Gillette Defence
This is such a defence that can be said to be a combination of both the defences
of invalidity and non-infringement and, in fact, is somewhat like striking at the
validity of the patent based on proving non-infringement of the patent, and is
a way of arguing non-infringement by proving invalidity without requiring the
patent claims to be construed. The argument is that in circumstances where
the patent is capable of two constructions - one wide and one narrow - the
defendant gives the plaintiff a Hobson's choice: if you construe the claim
narrowly, the defendant does not infringe; construe the claim broadly and it
encompasses the prior art which invalidates the patent. 2l
21

Janice M. Mueller, An Introduction to Patent Law,
ISBN-IO: 1454822449) 2012

85
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According to Terrell," Gillette defence is, ''An Infringement not Novel' (Gillette
defence) . Since no relief could be obtained in respect of an invalid patent, if
the defendant could prove that the act complained of was merely what was
disclosed in a publication which could be relied on againsr the validity of the
patent, without any substantial or patentable variation haying been made, he
had a good defence. "
The defendant argues that the patentee had been using a product or process
that was known at the time of the patent (i.e., patentee is recreating the prior
art), and since the product or process is covered by the patent then , the patent is
invalid on the grounds of obviousness and prior art. The de fendant's argument
is that if the plaintiff assertS a broad interpretation for its patent claims so as
to read onto the allegedly infringing product, the patentee runs the risks of
having its patent anticipated by the prior art. If the claims are interpreted too
narrowly to avoid a novelty attack, the alleged infringing product might fall
outside the scope of such an interpretation. Either way, the defendant wins if
the Gillette defence is effectively deployed.
The court shall then make a comparison of three-versions of the invention.
Firstly, the alleged prior art within the claims of which the defendant alleges that
the patented invention rightly falls. Secondly, the patented invention itself as
is claimed, by broadly construing the claims as fat as the ptiot art is concerned
and narrowly construing it as far as the defendants patent is co ncerned.
Thirdly, the court shall construe the claims of the defendant and determ ine
whether the defendants patent is broad enough to fall within the suspicion of
the claimed invention Ot that the patented invention is itself something that
is mere extension of the prior art and is something that is already there in the
public domain.
This defence was propounded by the court in the case of Gillette Safety Razor

Co v Anglo American Trading Co Ltd,2' where the allege infringement was
22

Terrell, 7<",11 on Patents, 8,h edition p.1 70

23

[1913J 30 R.P.C. 465

86
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defended on the grounds that the infringement was obvious. Gillette alleged
that the defendant had infringed its 1902 patent for an improved safety rawr.
The difficulty for Gillette was that the alleged infringement was almost identical
to an item in the prior art base. The patent in this case was for an improvement
of safety rawrs, the main feature being a thin Rexible razor blade clamped in a
curved holder by the handle. The effect of such clamp was to make the blade
rigid. The alleged infringement by the defendant also consisted of a similar
razor in which the blade was Rat. The defendant pointed out the existence of
American prior patent which involved the use of the handle as a clamp to hold
the razor blade. He argued the defence of invalidity and non-infringement.
Hence, this way, if the claims of the patent were interpreted widely so as to catch
what defendant had done, the patent would be invalid because it was anticipated
by prior art. On the other hand, if the patent was narrowly construed, the
defendant patent would fall outside the limits of patentees' claims."
Further in Page v. Brent Toy, Z2 the Court explained the limits of the Gillette
defence and stated that it is not a separate defence, but rather a convenient
form of raising an alternative plea of invalidity and non-infringement.

Gillette Defence in India
As far as its application to the Indian law is concerned, the issue came for
consideration before the court in] Mitra and Company Private Limited v. Kesar
Medicaments.'G The case involved a claim of infringement of the patent of the
plaintiff in respect of a device for detection of antibodies to Hepatitis C Virus
in human serum and plasma. The defendant in his turn submitted that even
ifhis ptoducts or diagnostic kit falls within the four corners of the said patent,
it would not constitute infringement as the impugned product was based on a
prior US patent. In the instant case, ruling our the possibility of the application
24

Helen No rman, Im,lImuai Property Rights, (O XFORD UNIVERSITI' P RESS, 20 14, ISBN0199688109, 9780199688104) (available at- https: llbooks.google.co.in /books?id=mO
VZAw AAQBA] &dq =gillene+defence+parent&source=gbs_navlinks_s)

25

(1950) 67 RPC 4

26

2008 (36) PTC 568 (available at-indiankanoon.org/dod 947992/)
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of the Gillette defence, the Court held that the defendants product directly fell
within the limitations of the claims made by the plaintiff, and that the patent
was not based on prior art as alleged by the defendant.
There has not been much significant development in this regard, and it is only
on the basis recognition of persuasive value of its application abroad can the
inherent meaning and intent of the same be realised in the Indian context. In
India, such defences are only employed by way of proving that the invention
has its roots in prior knowledge, or prior use and art and hence is devoid of
any element of novelty.
b) Prosecution History Estoppel and Reverse Doctrine of Equivalence27

The essence of inventions applied for the grant of patent lies in the claims
and it's the claim construction that forms the genesis of decision in a patent
infringement suit. Something that is not claimed is deemed dS being disclaimed,
and some.rhing that has been amended is deemed to have further limited the
scope of the claims. It is this determination of infringemen t that may either be
'literal infringement' or may be said to have been infringed by virtue of 'doctrine
of equivalence' (DOE) . The former occurs when each and every element in the
claim is proved to have an identical correspondence in the allegedly infringing
invention. Under DOE, an accused article or method that may not literally
meet the limitations of a claim, may nevertheless infringe if the accused article
is equivalent to the claimed invention.28 Therefore, even if there is no literal
infringement, but the accused product fonctions in the same way, to produce the
same result as that of the patent in question, liability entails. Hence, these are
such means at the disposal of the patentee that expands "he scope of patent
protection and enhances the chances of liability of the defendant. T he test to
determine equivalency is whether the difference between the feature in the accused
device and the limitation literally recited in the patent claim iJ "insubstantial" and
so there is infringement. 29

27

Elizabeth Verky, Law o[Patents,
870-6) p.320

28

Graver Tank & Mjg. Co. v. Lintk Air Products Co.,339 U.S. 605 (1 950)

29

Warner-Jmkimon Co. v. Hilton Davis Chern. Co., 520 U.S. 17 (1 <)97)

( EAsrERN

BOOK COMPANY, ed. 2005, ISBN-81-7012-
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However, as against this the defendant has at his disposal cwo defences that act
as a limitation to the DOE - the Prosecution history estoppel (PHE) and the
Reverse Doctrine of Equivalence (rDOE).
I.

Prosecution History Estoppel: The PHE, also known as the file-wrapper

defence,3o is a judicially created doctrine that estoppes the plaintiff from
employing the DOE to prove infringement ifhe had amended the scope
of his patents during the prosecution of his patent application so as
to limit the scope of his claims to be brought within the ambit of the
patent law. A patentee shall be precluded from contending infringement
by way of DO E against an alleged infringement if the subject matter of
the claims were surrendered by the patentee during the prosecution of his
patent by way of amendments. The PHE, therefore, restricts or bars the
patentee from claiming a right which he has earlier waived and arms me
defendant to escape from any liability of infringement. The defence can
be raised - where there is no literal infringement, the patent owner asserts
infringement by equivalents, and the accused affirmatively asserts the
defence of PHE that it prevents the patentee from asserting the DOE,
as the relevant subject matter has been disclaimed during prosecution .
Even unmistakable assertions made by an applicant shall also operate ro
preclude the patentee from asserting equivalency.
It was in Warner-Jenkinson Company, Inc. v. Hilton Davis Chemical CO.,3l that
for the first time the court limited the scope of application of the DOE in cases
where the reasons for the amendments remained unexplained in the prosecution
history; the burden lies on the patentee to establish the reasons thereof. Where
no such reasons are accorded the presumption shall rely on the fact that such
amendment was essential to fulfil the criteria of patentability, and such an
unrebutted presumption of the PHE acts as a complete bar to application of
30

The term was for the first time coined in Kelwgg Switchboard & Supply Co. "s. Michigan
Bell Tel. Co. [5 F. Supp. 118, 119 (E.O. Mich. 1933)[, whereas, the term PHE appeared
for the first time in Hughes Aircraft "s. United Staw [7 17 F.2d 1351, 1362 (Fed. C ir.
1983)J

31

520 U.S. 17 (I997)
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DOE in a disputed claim limitation. It was held that the DOE is to be applied
to each individual element of the claim, and not to the invention as a whole.
Later, it was in Festo Corporation v. Shoketsu Kinzoku Kogyo Kabushiki Co.
Ltd32 that pertained to invalidity and infringement claims in an invention
for 'magnetically coupled todless cylinder' that the COllrt described in its
entirety the scope and application of PHE as against the DOE. Initially, the
Federal Circuit observed that the PHE was a complete bar to the application
of the DOE, and that in cases where the scope pf the patent was nartowed by
way of amendments for the sake of patentability, there remains no scope for
infringement on the grounds of equivalence. However, on appeal the Supreme
Court reversed and remanded, and preferred a 'presumptive bar' apptoach to
DOE. This presumptive bar apptoach holds that where claims are amended,
"the inventor is deemed to concede that the patent does not extend as far as the
original claim" and the patentee has the burden of showing t hat the amendment
does not surrender the particular equivalent. For this the patentee shall have
ro prove that:

•
•

the equivalent was unforeseeable at the time the claim was drafted;
the amendment did not surrender the particular equivalent in
questIon; or

•

there was some reason why the patentee could not have recited the
equivalent in the claim.

Hence, due ro such an observation, the initial burden has shifted upon the
patentee ro prove the fact of infringement on the grounds of DOE, and in
case of failure of the same, the defendant shall easily have the defence on the
grounds of PHE.33 The test is a three-stage test:

•

Whether the amendment narrows the scope of the claims'

•

If so, was it carried out ro meet the criteria of pate ntability?

32

535 U.S. 722 (2002)

33

Su,EMD Millipore Corp. e' aL v. Allpure Tech,., Inc{Fed. Cir. Sept. 29, 201 4); Pacific Coas,
Marine Windshields L,d v. Malibu Boats, LLC, Fed. Ci r. Jan. 8, 20 [4); Trading Tech,. Int%
lnc. v. Opm E Cry LLC, (Fed. Cir. Aug. 30, 2013)
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•

If the presumption is deemed true, then the parenree is presumed
to have surrendered and waived all that was claimed earlier and is
barred under PHE.

n.
,

Reverse Doctrine of Equivalence: Another defen ce available to the
defendant as far as his defence relates to negating allegations of
infringemenr on accounr of idenrity of claims is that of Reverse Doctrine
of Equivalence (rDOE). The "normal" DoE extends the scope of a patenr
beyond the literal bounds defined in the claims to prevenr an infringer
ftom making insubstanrial changes or unforeseeable minor improvemenrs
in the invenrion as a way to avoid infringemenr. The reverse DoE, on the
other hand , conrracts the scope of a patenr to allow a literal infringer to
escape sanctions such as to prevenr a patenree from extending the reach
of the claims beyond the fair scope of the invenrion.

[n Hoffmann-La Roche Inc. v. Apotex Inc., }4 the Supreme Court observed that,

" Where a device is so for changed in principle from a patented article that it performs
the same or similar fonction in a substantially diffirent way, but nevertheless foIls
within the literal words of the claim, the reverse doctrine of equivalents may be
used to restrict the claim and defeat the patentee's action for infringement. "But,
it was also added that ' this doctrine is rarely applied, and this court has never
affirmed a finding ofnon-infringement under the reverse doctrine ofequivalents. '
Thus, where an invenrion relies on the fundamenral concept embodied in a
patenr but is more sophisticated than the patenred device due to a significanr
advance, the accused device does not infringe by virtue of the rDOE. [t is
applied by the courts to find that an invention does not actually infringe on
a patenr even if it technically does. In determining whether or not to use the
reverse doctrine of equivalenrs, a court will consider several factors :
}>

What is the actual scope of the patent' Does it cover the new
invention?

34

Fed. C it. Apt. 11 , 20 14(available ar·www.patentdocs.org/ .. .Ihoffman-la-roche-inc-v·
apolex.inc-fed-cir-2014) .
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If so, should that patent extend to the new invention ? This is the
major issue that the reverse doctrine of equiv ents must address.
What is the fair scope of the patent?

~

Has the new invention sufficiently transformed the original invention
such that it should fall outside the scope of the patent of the original
invention ?

PHE and RDOE under Indian Law: Under the Indian patent Act, 1970, the
provision for amendment to the application of patents or complete specification
(CS) or any document thereof can be made under the provisions of S. 57 and
5.2. of the Act at any time either before or after the grant of the patent. It is
imperative that such an application proposing amendment must state the nature
of the proposed amendment and shall give full particulars of the reasons for
which the same is being made. An application for amending the CS may also
include an amendment of the priority date of the claim. However, every such
amendment must be made in accordance with the following guidelines'5:

35

~

They must only be made by way of a disclai mer, correction or
explanation;

~

No such amendment shall be allowed except f r the purposes of
incorporation of actual fact;

~

In case of amendment of CS, an amendment shall not be allowed if
is such as to give effect to something in the speci cation that claims
or describes a matter not in substance disclosed or shown in the
specification before the amendment;

~

No such amendment must be such that any claim of the CS that is
amended would not fall wholly within the scope of any claim of the
specification before amendment.

~

The scope of the invention must not be widened by such an
amendment, as a patentee cannot be allowed to make a claim for a

Indian PatmtAct, 1970, Section 59
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monopoly right which was nOt included in the specification earlier.
Apart from these, 5.54 provides for improvement of, or modification in, the
invention described or disclosed in the specification when an application for
grant of patent has also been filed for such invention the applicant has also
filed before the Controller, who may grant in favour of such improvement as
a Patent of Addition. However, it is important that such improvement must
be more than a mere workshop improvement.
In Ravi Kamal Bali vs. Kala Tech, 36jt was held that finding of equivalence is a
determination of fact, and proof can be made in any form through testimony
of experts skilled in the field or an authoritative document on the subject.
The proofs are highly technical in nature and involve a detailed analysis of
the scope of claims, and it is crucial that the court understand the issue before
granting an injunction order. In this case, although the court initially applied
DOE, injunction was not granted on the ground that the material aspect was
represented erroneously. It was also implied that if there is question of validity
of the patent itself, then the injunction on the modification or improvement
later will not be gtanted. In this case, it was stated that DOE is an important
principle to cover direct or literal infringement under patent law.
Until now, in India there has not been any significant application of the PHE
or rDOE in any case at hand, and nor is there any explicit provision under
the provisions of the Act to infer its application and use. As such , the relation
of such provision under the Patents may be made in relation to the Doctrine
of Estoppel as enumerated under the Indian Evidence Act, 1872 uls. l 15.11. A

36

[2008(110) Bom.L.R.2167]

37

Indian Evidence Act, 1872, Section 11 5 states: "When one person has, by his declaration,
act or omission, intentionally caused or permitted anotha person to believe a thing to be true
and to act upon such beliif, neitha he nor his representative shall be allowlCi, in any suit or
proceeding between himself and such p erson or his representative, to deny the truth of that

thing. "
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bare reading of the provision indicates that once a statement has been admitted
to which has the effect of forcing another person into believing into the truth
of the statement, then the person making such statement is estopped from
denying the truthfulness of the same. Hence, once you have admitted a thing,
the same cannot be denied at other time. The intent and purpose of this
provision is similar to the intent underlying the doctrine of PHE. Moreover,
since in the cases of infri ngement, it is the evidence of both the parties that has
to be raken into consideration, and since PHE is one of the primary evidences
ro be considered by the court while interpreting the claims in an infringement
suit,' · rhe principle objectives underlying its application and use may also
be imported to the Patent Act, and the courts may take into consideration
the criterion stipulated under the Evidence Act to be synonymous with the
on e required to bar the patentee from declaiming the fact of the claims and
limitations incorporated into the claims of the invention by way of amendment,
when the same is without any reason or justification.
The fact that ~a pre-condition for application of amendment is that the
amendment must state the reasons for the proposed amendment and, also,
provide the fall particulars of the reasons for the same. Thi, may be related to
the principles underlying the PHE doctrine that may be successfully pleaded
by the defendant as a defence in cases where the patentee fai Is to assign reasons
for amending his patent and amends the same for fulfilling the patentabiliry
criteria. In such cases, the patentee shall be barred by application of PHE
to plead DOE to prove infringement. This may indirectly be construed as
indicating the application of either DOE or PHE based u on the fulfilment
or non-fulfilment of the conditions stipulated therein, res pectively. Further,
S.59(3) provides that while construing the amended specificatio n, reference
may be made to the specification as was originally accepted, i.e., the initial
specification . This may also be deemed as being an indirect reference to the
PHE.

38

Ma rkman v. W<tvinu InslTUmmcr Inc.• (52 F.3d 967 (J 995) 63 USLW 2663 . p.7(available
at- http: //www.oceanromo.com/system/files/MarkmanvWestviewil lstrumentslnc_O.pdf)
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(C) TYPES OF CLASS DEFENCES
Class defences are such that they help in defending the entire class of the
probable infringers who are engaged in the use and exploiration of the patented
invention. These are such uses that are in the public interest, and this is one of
the most crucial factors that may help in defending against the infringement
allegation. Two of such defences that have been expressly laid down under the
Indian Act are those relating to Parallel Importation and Bolar exemption, while
another defence is that of research or experimental use wh ich is not expressly
provided under the Indi an Act, but is followed in US and UK. The following
shall be discussed at length in the present section .

a) Parallel Importation
The term parallel importation is nowhere defined or used under the Indian Acr,
but the same is implied in the wordings of the Section l07A(b Jwhich provides
for international exhaustion, thereby providing a considerably liberal patent
infringement defence. The term find s mention in the Statement of Objects
and Reasons appended to the Patents (Second Amendment) Bill, 1999, which
became the Patents (Amendment) Act, 2002.39 Parallel importation is in fact
an antithesis of the doctrine of Exhaustion that is widely recognised under
other jurisdictions, under which the rights of the patent owner are deemed
to have ex~austed over the royalty or other such monetaty gains that accrue
in subsequent sales after the very first sale of his patented invention. It may
be said to be a natural consequence of doctrine and represents a form of price
arbitrage whereby a legitimate product is imported from the market intended

39

The Palents (Second Amendment) Bill, 1999 (which eventually became the Paten ts
(Amendment) Act, 2002) was introduced in the Parliament on 20th December, 1999.
(available at- http://rajyasabha.nic.in/journalsI188/20 121999.htm.) Thereafter, a motion
was passed and adopted by the Rajya Sabha on 21 December 1999 and by the Lok Sabha
on 22 December, 1999, to refer the Bill to a Joint Committee ofboch Houses ofParliamenr
(available at- http://www. pariiamenrofi ndia.nic. in/ls/ bulletin 2/0IlDI SII 0I.htm . The
Bill was placed before the Raj ya Sabha for consideration on 9 May, 2002. (avai lable at·
h np: II co mmerce. n ic.i01press rdease! pressrelease_detail .as p?id = 8 80)
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by the patent holder ro another market where it can be sold at a higher price'o
Parallel importation is closely associated with the exhaustion, because parallel
importation can be defined as: "the importation of a good or service as ro
which exhaustion of an IPR has occurred abroad is commonly referred ro as
Parallel Importation."
'Exhaustion' refers ro the lapse of the exclusive right of distribution of the right
holder, who loses or 'exhausts' certain rights with regard ro one specific product
after the first use of the subject matter, once the product has entered the market
with the consent of the right holder." The doctrine of exhaustion imposes
certain limits on the patentees' exclusive rights. According ro this doctrine, "a
patented item's initial authorized sale terminates all patent rights ro that item.""
Consequently, the patentee cannot control the resale or re··distribution of the
particular item that has already been sold once.
The term "parallel importation" refers ro goods produced a d sold legally and,
subsequently, exported. Grey and mysterious may only he the distribution
channels by which these goods find their way ro the importing country" It
is here that such imported good, or for that matter the patented invention
when imported in a country, are not considered infringing and, thereby, in
competition with the invention of the patent holder due to the application
and prevalence of the exhaustion doctrine in the country t which such goods
are imported. Lawfulness of parallel imports, defined as importS without
authorization from the right holder of patented goods fro m the third country,

40

Gene M. Grossman & Edwin L. C. Lai, Para"" Imports and ?ria Controls, 39 RAND
J. ECON. 378, 378 (ISSN 0741 -6261 ) 2008

41

UCTAD-ICTSD, R.Jouret Book on TRIPS and Dro<lopmmt, (New York, Cambridge
Un iversity Press 2005, ISBN- ISBN-l3: 0521850445-978)), p.93.

42

Hiroko Yamane, Inurpm ing TRIPS: Globalisation ofIntelkctu4I?r,pmy Rights andAccm
to Medicin", (Hart Publishing Ltd. , UK, 20 II , ISBN- )

43

Quanta Computer, Inc. v. LG EkctronicJ Inc. , (No. 06-937) 453 F. 3d 1364 , reversed
(Supreme Court June 9, 2008

44

Christopher Heath, Paral'" Imports and Inurnational Trade, Vol. I (1999), (available at
hcrp:!!www.wipo.im!edocs! mdocs!sme! en! atrip _gva_99! acrip...gv a_99 _6. pdf)
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depends on the exhaustion regime of a country, i.e., whether the country
adopts policies of national, regional or international exhaustion. Depending
on the policies that a country adopts, right holders may be unable to enforce
particular rights in another jurisdiction." Were it not for such "exhaustion" of
rights, a purchaser of a patented article might be prevented from selling the
said item or even "using" it, since such "sale" or "use" implicates the exclusive
rights of the patentee. 46
Hence, these goods that are imported are not unauthorised, per se, bur are such
goods where there is no express authorisation but are legitimate goods brought
from the legitimate sale of the good. The only right that the importer of such
good is conferred with is that of the right of distribution of such goods, without
further obtaining consent from the right holder of the said good. The alleged
infringer may bypass the exclusive rights of the patentee and make use of the
patented invention to his advantage without any liabiliry, but for this defence
of parallel importation.
b) Regulatory or Prior Use defence (Bolar Exemption)

Another exception to the patent rights is the Research Exemption which may
be used as a credible class defence. These can be of two rypes: Putely scientific
in nature and Developmental research aimed at generating experimental data
with a commercial objective.

It is this latter type that is called the Bolar Exception in the patent parlance
and has derived its name from the famous case in the US "Bolar v. Roche
Pharmaceuticals" in 1984.47
45

UCTAD-ICTSD, Resource Book on TRIPS and Develcpment. (New York: Cambridge
University Press, 2005), p.92

46

Shamnaad Basheer, TRIPS. Patents and Parallel Imports in India: A Proposalfor Amendment.
INDIAN ] . INTELL. PROP. L.p.3 (available at-http: //www.nalsar.ac.in/ IJIPLIFiles/Archivesl
Volume%202/4.pdf)

47

Suresh Kumar, Patent laws and Research Exemption imperatives- do scientists have enough

feedom to operate! CURRENT SCIENCE, Vo1.99, No.ll, December, 2010 (available
at-www.currentscience.ac.in/ ...Iarticle_id_099_11_1523_1 529 _O.pdf)
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It was In order to comply with the TRIPS mandate that the Patents
(Amendment) Act, 2002, introduced the Bolar provision ro allow the use
and sale of the patented product during the term of the patent for obtaining
regulatory approvals. The amended Act 2005 has revised this to include the
act of importing as well. The provision has been selectively transposed from
the US law."
The origin of this exception dates back to the decision by the US Supreme
Court in Roche Products Inc. v. Bolar Pharmaceutical Co.12_where the Court of
Appeal held the competitors' use of a patented drug for the purposes of Food
and Drugs Authoriry (FDA) approval of its generic version to be infringing, in
spite of the fact that the generic drug was not marketed umil the expiration of
the patent term, thereby closing doors for the generic companies to enter into
the market immediately after expiry of the patent term. After this judgement,
the US Congress passed the Hatch-Waxman Act, 1984,50 that sought to amend
the Federal Food Drug and Cosmetic Act and introduced a process for New
D rug Application (NDA) that extended the patent term aher the grant of the
FDA approval and created an Abbreviated New Drug Application (ANDA)
process for generic drug developers to obtain the FDA approval ."

48

Saurabh Chandra, IMPACT OF TRIPS OVER INDIAN PATENT REGIME VIS A
VIS INDIAN PHARMACEUTICAL IND USTRY, G]LS Vol. I ,No. 1, p.4( ISSN. 23211997) (available ar-aw.galgotiasuniversiry.edu.in/pdf/issue4.pdf) 2013

49

733 F. 2d.858(C.A. Fed, 1984). In this case, Bolar intended to , ubmit an Abbreviated
New Drug Application (ANDA) [0 the FDA for a similar drug comaining the same active
ingrediem upon the expiry of Roche's parem. A shorr time before the expiry of the patent,
Bolar obtained some of the active ingrediem from a foreign manufacturer and began the

bioequivalency studies necessary for compiling the ANDA. Roche responded by fil ing
a suit for patent infringement. The District Court of the Eastern District of New York
found that no infringement had taken place owing to the "experimemal" nature of
Bolar's works.
50

The Drug Price Competition and Patem Term Restoration Act, 1984

51

35 USC Section 156 provides for the extension of the term of a patem for compensating
[he time lost in FDA approval, while SwiQn 2V(rJO) allowed generic companies to
emer the market as soon as the patem term expires by permitting them to conduct the
tests for FDA approval during the patem term.
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The so-called Bolar or early working exemption deals with the use of the
patented pharmaceutical product to conduct tests and obtain market apptoval
ftom the heal th authority, before the expiry of a patent, for commercialisation
of th e generic version , just after such expiry. This is done by submission of
info rmation to the drugs control authority and generating data by demonstrating
the bioequivalence of the patented drug while the patent is still in force without
obtaining consent of the patentee.52

Bolar Exemption under TRIPS
T he recognition of this exception is implied under the Exceptions to Patent
Righ ts under Article 30 a/the TRIPS. T he consistency of the Bolar exemption
with the provision under Article 30 came for co nsideration before the WTO
panel in Canada (Canada-Patent Protection for Pharmaceutical Products)22 in
which, while upholding the incorporation of the Bolar provision under its
domestic law in Canada, s4 the panel observed that the practice of allowing
the development and submission of information required to obtain market
apptoval for pharmaceutical ptoducts carried out without the consent of the
patent holder fulfilled the T hree-step test under Article 30 of the TRIPs and
maintained an equitable balance between the rights of the patent holder and
public interest.

52

Carl os M. Correa, TrtUk-Related kpects ofIntellectual Property Rights - A Commmtary on
the TRIPS Agrument, (Oxford University Press, Edirion 2007, ISBN-9780 199271283)

53

Canada - Patent Proteccion ofPharmaceutical Products, WT IDS 114/ R, 17 March 2000

54

Section 55.2 ofCcmadian patent law, which provided·
"(1)

It is not an infringement ofa patent for any p erson to make, construct, use or uti the
patmud invention sokLy for uses uasonably related to the devdopment and submission
a/information required under any law ofCanada, a province or a country other than
Canada that regulates the manufacture, construction, use or sale ofany product.

(2)

It is not an injTingnnmt of a paunt for any person who makes. constructs, uses or
sells a patented irwtntion in accordance with subuction (1) to make, constroct or use

the invention, during the applicahle period provided for by the regulations, for the
manufacture and storage ofArticles inttnded for sale after the date on which the term
of the patent expires. "
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Application and Use of Bolar Exemption in India
The 2005 Amendment to the Indian Patents Act, 1970, was made to give effect
to the Bolar exemption provision in those instances when an invention is used
or sold by a third parry for purposes related to research and development.
A plain reading of the bare provision u/s .107A(b) " implies that any act of
making, selling, importing of the patented invention when is related to purposes
involving the development and submission of information under any law that
seeks to regulate such manufacture, construction, sale or import, in India or
elsewhere, shall not be an infringement.
The provision came for consideration before the Delhi High Court in the
(NPL)% in which
case of Bayer Corporation (Bayer) v. Union ofIndia &

o,·s

the question for consideration was not exactly related to the interpretation of
the provision under S. 107A(a), but whether its scope and application were
broad enough to include the export of patented drugs to other countries for
the purpose related to research and development. The court had to consider
whether Section 107A covered export of a patented product for use by an
overseas importer to conduct studies and generate data for the purpose of
seeking regulatory approval in that country. Opining in the affi rmative, the
Court upheld the export by NPL of the generic version of the drug patented
by Bayer, Sofranet, to China on the grounds that the provision un der the Act
was broad enough to include sale of the patented product for development
and submission of information under any law in force in a country, apart from
India, and hence the sale of the drug to HPCL in China for submission of
studies and data related to bio-equivalence and bio-availabiliry of the said drug

55

Section 107A(a) provides that: "any act of making, constructing. usmg. selling or imponing
a patented invemion solely for uses reasonably related to the development and submission
of information required under any law fo r the time being in force, tn India, or in a coumry
other than India, that regulates the manufactu re, construction . u~e. sale or import of any
product. shal l not be an infringement of a patem. "

56

CM 9687/ 20 14 in w.P.(C) 19711201 4 (available at-http://lobis. ni c.in/dhcIVIB I
judgement/07-11-2014 /VIB0511201 4CWI 97 12014.pdf)
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in a generic version is said to be related to the studies required for regulatory
approval . While interpreting 'reasonably related to'used in Section 107 A to mean
a reasonable nexus, it held that the same exists between the sale ofSorafenat by
NPL to HPCL and submission of information under the law in force in China.

CONCLUSION
It is an undeniable fact that the defences do playa very crucial role in deciding
the fate of an infringement action against the defendant, especially in cases
when the defendant seeks to prove non-infringement by striking at the validity
of the patent. However, employing a successful defence involves a proof beyond
doubt that the claims made by the defendant fall outside the limits set by the
plaintiff in his claims. It is the claims and their interpretation that defines the
boundaries and limitations of the invention that culminates into determining
the liability of the defendant.

FINDINGS
The defences available under the Act challenging the validi ty of the patent
have not been precisely and succinctly worded in a language that may be
identified with the intent and purpose of that defence, and some of such
inherent ambiguities lie in the following provisions due to absence of any
definitional clarity about the same and, hence, leaving wide scope for a subjective
interpretation on a case

•

[0

case basis:

The word infringement has nowhere been defined in the Act and is to
be governed indirectly by interpreting the provision u/s.48 that confers
exclusive rights on the patentee undermines the completeness of the Indian
Patent Act.

•

The provision u/s.3(d) which may be employed as a ground of defence
based on invalidity of patent fails to delineate the meaning and purpose
inherent in the word 'enhancement of known efficacy.' Despite the
Novartis judgements' clarification that it is synonymous with therapeutic
enhancement, what factors shall constitute such enhanced efficacy remains
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undefined as far as other products and processes are concerned . Moreover,
there can't be a strait jacket formula for the same, as determination of the
same shall have a subjective interpretation, rather than an objective one.
•

Section 107 r/w. S. 64(e) seeks to invalidate a patent on the grounds that
the claims are not new owing to a 'prior public knowledge or public use in
India before the priority date.' What shall constitute such public use and
whether it includes any commercial exploitation is not clear. Judiciary
interprets it to mean 'a use in a public manner, ' but this also seems vague
and incomplete when an allegation of infringement is to be defended by
proof of a prior knowledge about the same.

•

Absence of any clarity on what may be deemed as a gro und fo r invalidating
a patent obtained by false suggestion or misinterpretation under S. 107
r/w. S.64(j) casts a doubt on the wisdom of the examiners and patent
officers who are enjoined with the responsibility of undertaking a thorough
examination of the patent before its grant.

•

S.64(d) and (k) are repetitive in the sense that they provide for the same
grounds of invalidity on the basis of non-patentability of invention u/ s.
3 and 4 of the Act.

•

Further S.64(1) implies a secret use of the invention in India by a patentee
to be a conduct that shall not provide immunity to the patentee in a suit
for infringement.

With regard to the Class defences, namely Parallel Importation u/s.l 07A(b)
and the Bolar Exemption u/s.107 A(a) also exhibit the following ambiguities:
i)

Parallel Importation

•

The fact that importation of the patented inventi n may be employed
as a defence outrightly undermines the exclusivity in rights conferred
upon the Patentee in regard to importation of his patented invention
u/s.48.

•

There is no clarity in the language that may i dicate that it is in
fact the patentee who has authorised the first sale, and therefore the
102
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subsequent sales or importation thereof may be considered to be a
legal importation and, therefore, a valid defence.

•

The basic principle ofIntellecrual Property is that they are territorial
in nature, but the defence of PI overshadows this age-old principle
of IPRs .

i i)

Bolar Exemption

•

The fact that such development and submission of information is
merely for the purpose of obtaining market approval is not indicated
in the language of the provision u/s. \07A(a).

•

Nowhere in the provision has the term 'market apptoval' been
expressly referred to, and thus there arises ambiguity with regard to
what has been interpreted and construed by the courts to infer the
meaning that such information is for purposes of market approval .

•

That such market approval may be taken for the purpose of sale and
export is inconsistent with the very object of Regulatory or prior use
defence that only permits obtaining a market approval without any
commercial exploitation before the expiry of the term of patent.

•

The term 'uses reasonably related to development' is a subjective
term that doesn't find any clear definition or meaning under the
statute, thus giving rise to doubts about what constitutes reasonable
use, the quantity of the drug to be used for such purposes, issues of
permitting stock-piling of drugs, etc.

•

That the information for submission and development as required
under the law in India or in any other country indicates that such
research experiments may be carried out either in India or outside
India. Hence, this indicates that there shall definitely be a commercial
intent behind such submission of information and the work that
shall be done upon that.

•

That there is no mention about the time period after which such
application for market approval needs to be made by the generic
103

National Law School journal

Vol. 13

20 15-1 6

companies, and there is no mechanism to monitor that such drugs
are not commercially exploited before the expiry of the patent term.
o

That the ptovision doesn't specifY clearly whether such Regulatory use
should be 'on' the patented product or 'with' thl! patented product,
as it is in the former that the true essence of th e Bolar Exemption
can be realised.

o

Section 64 Clause3(a) excludes a reasonable trial or experimental use
from constituting a secret use for the purpose of invalidity of the
patent. However, it is not clear if such secret experimental use shall
include the experiments on the patented invention ufc.! 07A(a) also.

The provisions related to individualised defences have not been expressly
provided for under the Act, but the same may be inferred from the interpretation
of the inherent meaning of the provisions under the Act.
o

The Gillette defence that employs a combination of both types of
defences such that it seeks ro prove non-infringement by attacking
the validity of the patent may be inferred as bein l~ synonymous with
the defence that seeks ro challenge the validity on account of prior
art or prior public knowledge and use of the elements constituting
the invention alleged to have been infringed.

o

That although the Govr. is deemed as being bound to the rights
conferred on grant of patent upon the patentee, the exceptions that
are reserved by the Patent office to be imposed as conditions against
such grant by way of allowing the use of such invention by the Govt.
adversely affects the rights of the patentee. Moreover, on ufs .99
and! 02, the Govt. has been empowered to ac uire the invention
on payment of remuneration to the patentee. However, even an
adequate compensation for such use shall be nothing in comparison
to the labour, effort, time and intellect employed by the patentee in
making the invention.

104
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,

That, since [here is no explicit mention about the use of PHE as a
defence to infringement sui", rhe same may be inferred from the
wordings ofS.57 and 59 that stipulate specification and description
of the reasons for the amendment. This may be related ro the
concept under PHE which doesn't allow the patentee ro contend
infringement in cases where the amendment has been made on
grounds that required fulfilment of patentabiliry. Moreover, the
fact that PHE involves evidential proof of the claims and the
amendments incorporated during the prosecution of the patent, the
rules governing Doctrine of Esroppel under the Evidence Act may
be imported ro be applied ro patents.

SUGGESTIONS AND RECOMMENDATIONS

As with all laws, the devil is in the details. So is the case with the Indian Patent
Act, 1970, in which although the intent of the framers and legislarors was ro
protect the rights of the patentee and accord him the exclusiviry against all
unauthorised use of the invention developed by him, but the same is not very
succinctly inferred from the provisions of the Act as the same are shadowed
with certain inherent ambiguities. It is the language of the provisions which
have not been drafted with precision and accuracy that has left open certain
gaps which create confusion and interfere with the rights of the patentee ro
realise his rights in the true spirit of the term.
The following are the changes that may be incorporated ro the statute as far as
the provisions under parallel importation are concerned57:
~

The provision must clearly state that the defence is in regard ro parallel
importation and exhaustion of the rights of the patentee and that the
rights of the latter shall stand exhausted after the first sale of the article
under authorisation from such patentee.

57

Shamnaad Bashee r, 'Exhausting' Pau nt Rights in India: Parallel Imports and TRIPs,
Compliance, 13 JOURNAL OF INTELLECTUAL PROPERTY RlGHTS, (available
at.http://nopr.niscair.res.in /bitstream/ 123456789/2037/ 1/JIPR%2013(5)%20486·497.
pdf)2008
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:..

The same may be limited in scope in case of any co ntractual agreement
when such agreement relates to fulfilling of purposes related to , or
incidental to , the functions of the Govt. or public interests.

:..

The importation shall only be valid when there has been an express
authorisation on the part of the patentee and it has been agreed to share
the profits such as may be adequate and reasonable.

:..

There shall be exhaustion of the rights of the patentee once there is a sale
of the components that 'substantially embodies' or 'essentially embodies'
any patent granted under the Act and the sale of such component was
made with the express authorisation of the patentee.

:..

The exception shall encompass both method and process patents, apart
from product patents, also.

Since Bolar Exemption is only one part of the remedy fo r ensuring generic
drugs be rolled out in the market as soon as the patent shal l expire, there must
be incorporated provisions for giving effect to the Data exclusivity provisions
in the Act, so that there are rights of the patentee with respect to ensuring an
extended term of protection and market exclusivity of the patent in question .
Although vide the 2001 Amendment to the Drugs and Cosmetics Act, 1940,
the provisions fo r Data protection have been included to ensure an easy and
expeditious entty of generic drugs by a proof ofbio-equival<:nce of the patented
drug and are granted approval on the basis of the test data already submitted
by the previous applicant or the patentee himself, but this still goes on to affect
the exclusivity in rights as maintained and ensured by the minimum standards
laid under the T RIPS.
Also, the sense and the purpose of this exemption shall become well defi ned
once it is clearly specified that the research and development and the submission
of the information for the purposes of obtaining market approval is 'on' the
patented drug, rather than 'with' the patented drug. Although this may be a
small difference, it is capable of causing huge implications upon the way the
information is used and the further ramifications that the Bolar exemption
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seeks to create. In cases where it is specified as being a use for research and
development and submission of the information obtained 'on' the patented
drug, any sort of 'use' of the drug in the generic sense of the term is ruled out,
paving way for an unblemished and an unbounded exemption that encourages
generic development of the drugs for purposes solely connected to and related
with public health and public interest.
In cases where the research is not expressly for generic companies, consideration
with regard to use of the patented drug and the information thereof must be
considered in the light of licenses, or acquisition may be considered in the
interim. Thus, there is a need to include the ptovision regarding Data exclusiviry
in the Act, so as to also ptotect the rights of the patentee which is the sole
objective behind the enactment of the Act.
Since, under law, a person may be both legal and natural and such legal
entities are inclusive of Companies and agencies or partnership firms, under
patents, also, it may be inferred that such persons are also eligible for holding
a patent and being conferred with the exclusive rights. It is in this context that
the implication and intents of the 'shop-right' defence may be included and
given statutory recognition. With the proliferation and promotion of more
and more industrial and technological development, the companies may also
be considered eligible enough to hold patents. Although 5.124 underlines the
offences by the companies, such as to include acts that are in contravention of
the provisions of the Act, a similar provision recognising its rights to hold and
enjoy patent rights by way of shop rights may prove beneficial.
The defences seem to have been incorporated with a biased intention in favour
of the defendant without paying sufficient heed towards intetests of the patentee.
It is thus imperative that in order to give effect to the policy objectives under
the TRIPS, which seeks to ensure a balance between the rights of the patent
holder and that of the sociery, it must be such that the promotion of science,
technology and research and development may also be endeavoured to be
simultaneously fulfilled.
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